Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Shares Outstanding (2020 - 2025)

Apellis Pharmaceuticals has reported Shares Outstanding over the past 6 years, most recently at $126.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $126.6 million for Q4 2025, up 1.71% from a year ago — trailing twelve months through Dec 2025 was $126.6 million (up 1.71% YoY), and the annual figure for FY2025 was $126.6 million, up 1.71%.
  • Shares Outstanding for Q4 2025 was $126.6 million at Apellis Pharmaceuticals, roughly flat from $126.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding for APLS hit a ceiling of $126.6 million in Q4 2025 and a floor of $80.4 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $118.0 million (2023), compared with a mean of $112.3 million.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 115125.78% in 2021 and later rose 1.71% in 2025.
  • Apellis Pharmaceuticals' Shares Outstanding stood at $97.5 million in 2021, then grew by 13.58% to $110.8 million in 2022, then rose by 7.93% to $119.6 million in 2023, then rose by 4.13% to $124.5 million in 2024, then grew by 1.71% to $126.6 million in 2025.
  • The last three reported values for Shares Outstanding were $126.6 million (Q4 2025), $126.5 million (Q3 2025), and $126.2 million (Q2 2025) per Business Quant data.